SCHEMBL4483306

SCHEMBL4483306

CC(=O)Nc1ccc2c(S(=O)(=O)NCc3ccc(C(C)(C)C)cc3)cccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.49
NR1H4 Q96RI1 1/20 0.49
LMNA P02545 3/20 0.46
HDAC3 O15379 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
SLC2A1 P11166 1/20 0.44
NAMPT P43490 1/20 0.44
NSD2 O96028 2/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 2/20 0.42
HPGD P15428 1/20 0.42
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 3/20 0.41
RECQL P46063 2/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4474391 0.89 NSD2 (0.49) LMNANSD2KMT2AMEN1TP53
SCHEMBL4483600 0.82 LMNA (0.59) EPHX2NR1H4LMNAHDAC3HDAC8
SCHEMBL4480386 0.82 CASP6 (0.58) EPHX2LMNAHDAC3HDAC8HDAC6
SCHEMBL4482603 0.81 NSD2 (0.53) EPHX2HDAC3HDAC8HDAC6NSD2
SCHEMBL4453218 0.80 CCR8 (0.55) EPHX2NR1H4HDAC3HDAC8HDAC6
SCHEMBL8784533 0.76 CASP6 (0.59) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL4491082 0.76 NSD2 (0.57) HDAC3HDAC8HDAC6NSD2
SCHEMBL4472758 0.76 HDAC3 (0.54) EPHX2NR1H4LMNAHDAC3HDAC8
SCHEMBL4482015 0.76 MEN1 (0.47) LMNAKMT2AMEN1TP53ATM
SCHEMBL9747665 0.75 ALDH1A1 (0.57) POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 EPHX2 4809/4885NR1H4 957/4885LMNA 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.